Why anti-cancer drugs do not always live up to expectations

For more than a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that "Bromo- and Extra-Terminal domain" (BET) proteins help activate, so blocking BET proteins should slow tumor growth.

source https://medicalxpress.com/news/2026-04-anti-cancer-drugs.html